CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma
Autologous and allogeneic CAR T cell therapies led by BCMA lead to profound and durable responses in heavily pre-treated multiple myeloma patients with a low incidence of severe cytokine release syndrome and neurotoxicity. According to Yi Lin, in the near future we will no longer be limited by trial criteria for CAR T-cells. For example, […]